Who makes Candesartan plus non-CCB agents?

Candesartan plus non-CCB agents is developed by Kyorin University.

What development phase is Candesartan plus non-CCB agents in?

Candesartan plus non-CCB agents is FDA-approved (marketed).

Last reviewed 2026-05-15 · How we verify

Candesartan plus non-CCB agents

Kyorin University · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Candesartan plus non-CCB agents
Sponsor	Kyorin University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) (PHASE2, PHASE3)
CCB Safety Study in Treatment of Hypertension of ADPKD (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Candesartan plus non-CCB agents CI brief — competitive landscape report
Candesartan plus non-CCB agents updates RSS · CI watch RSS
Kyorin University portfolio CI